Cytori Therapeutics (CYTX) Trading Down 0% After Insider Selling

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) dropped 0% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $0.30 and last traded at $0.31. Approximately 1,821,500 shares were traded during trading, a decline of 25% from the average daily volume of 2,440,602 shares. The stock had previously closed at $0.31.

Specifically, major shareholder Ag Postfinance sold 236,155 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $0.34, for a total value of $80,292.70. Following the sale, the insider now owns 5,311,451 shares of the company’s stock, valued at $1,805,893.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the sale, the insider now directly owns 5,496,655 shares in the company, valued at approximately $2,088,728.90. The disclosure for this sale can be found here. Insiders sold 408,785 shares of company stock worth $142,987 in the last ninety days. Insiders own 1.90% of the company’s stock.

CYTX has been the topic of several recent research reports. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a report on Friday, January 5th. Zacks Investment Research raised shares of Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a report on Tuesday, November 7th. Finally, ValuEngine raised shares of Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Perkins Capital Management Inc. lifted its stake in shares of Cytori Therapeutics by 134.0% during the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares during the period. Vanguard Group Inc. lifted its stake in shares of Cytori Therapeutics by 81.9% during the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares during the period. Finally, Sabby Management LLC lifted its stake in shares of Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares during the period. 10.82% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Cytori Therapeutics (CYTX) Trading Down 0% After Insider Selling” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/cytori-therapeutics-cytx-trading-down-0-after-insider-selling.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply